To hear about similar clinical trials, please enter your email below
Trial Title:
Role of Endocrine Disruptors in Thyroid Cancer
NCT ID:
NCT05747365
Condition:
Endocrine Disruptor Chemicals
Thyroid Cancer
Conditions: Official terms:
Thyroid Neoplasms
Thyroid Diseases
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Blood and urine diagnostic evaluation
Description:
Blood and urine samples will be obtained from both case and control groups in order to
evaluate EDCs concentrations
Arm group label:
Case group
Arm group label:
Control group
Summary:
the relationship between human exposure to EDCS and TC is poorly investigated and still
unclear. The aim of this study is to evaluate the possible role of old and new generation
endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in
the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA,
PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates,
parabens, PCBs, flame retardants) between patients with and without a diagnosis of
thyroid cancer through highly sensitive, selective and precise mass spectrometry methods,
such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS).
The secondary aim is to evaluate the relationship between the concentrations of endocrine
disruptors and some anamnestic variables studied (for example the type of diet, the use
of personal care products).
Criteria for eligibility:
Study pop:
all patients referred to our tertiary clinical center for thyroid cancer diagnosed in the
last 5 years will be consecutively enrolled (case population). Patients without a
diagnosis of thyroid cancer will match patients included in the case population,
according to age and sex.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- patients with a diagnosis of thyroid cancer in the last 5 years (arm A)
- patients without a diagnosis of thyroid cancer will match patients included in arm A
Exclusion Criteria:
- subjects under 18 years old
- patients unable to sign the informed consent or questionnaires
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Istituto Auxologico Italiano, IRCCS
Address:
City:
Milan
Zip:
20149
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Laura Fugazzola, MD
Phone:
+390261911
Phone ext:
2727
Email:
l.fugazzola@auxologico.it
Start date:
July 12, 2022
Completion date:
July 31, 2025
Lead sponsor:
Agency:
Istituto Auxologico Italiano
Agency class:
Other
Source:
Istituto Auxologico Italiano
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05747365
